A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Yuuri HashimotoKumiko KoyamaYasuki KamaiKenji HirotaniYusuke OgitaniAkiko ZembutsuManabu AbeYuki KanedaNaoyuki MaedaYoshinobu ShioseTakuma IguchiTomomichi IshizakaTsuyoshi KaribeIchiro HayakawaKoji MoritaTakashi NakadaTaisei NomuraKenichi WakitaTakashi KagariYuki AbeMasato MurakamiSuguru UenoToshinori AgatsumaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
U3-1402 demonstrated promising antitumor activity against HER3-expressing tumors with tolerable safety profiles. The activity of U3-1402 was driven by HER3-mediated payload delivery via high internalization into tumor cells.
Keyphrases